NCT03739801View on ClinicalTrials.gov

MM-398 and Ramucirumab in Treating Patients With Gastric Cancer or Gastroesophageal Junction Adenocarcinoma

PHASE1/PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

April 6, 2020

Primary Completion Date

April 6, 2022

Study Completion Date

April 6, 2023

Conditions
Locally Advanced Unresectable Gastric AdenocarcinomaMetastatic Gastroesophageal Junction AdenocarcinomaMetastatic Unresectable Gastric AdenocarcinomaUnresectable Gastroesophageal Junction AdenocarcinomaGastric AdenocarcinomaGastroesophageal Junction Adenocarcinoma
Interventions
DRUG

Liposomal Irinotecan

Given IV

OTHER

Quality-of-Life Assessment

Ancillary studies

OTHER

Questionnaire Administration

Ancillary studies

BIOLOGICAL

Ramucirumab

Given IV

Trial Locations (1)

90033

USC / Norris Comprehensive Cancer Center, Los Angeles

Sponsors

Collaborators (1)

Ipsen
All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

collaborator

Ipsen

INDUSTRY

lead

University of Southern California

OTHER

NCT03739801 - MM-398 and Ramucirumab in Treating Patients With Gastric Cancer or Gastroesophageal Junction Adenocarcinoma | Biotech Hunter | Biotech Hunter